These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Decisions by the state, county council's money and my patient. Consequences of the LFN survey of antihypertensive agents]. André M; Andersén-Karlsson E; Landahl S; Löfmark R; Silfverhielm B; Skoglund I Lakartidningen; 2008 May 21-27; 105(21):1549-50. PubMed ID: 18574990 [No Abstract] [Full Text] [Related]
3. [Discontinuation of subsidizing of certain antihypertensive agents is not well thought-out]. Berggren B; Lindström T; Nyström F; Cizinsky S; Weiss L; Willenheimer R Lakartidningen; 2008 Aug 27-Sep 2; 105(35):2345-6. PubMed ID: 18831442 [No Abstract] [Full Text] [Related]
4. [TLV meets criticism: costs of antihypertensive agents can and should be reduced]. Edling A; Löfmark R; Vinge E; Carlsson P; André M; Melltorp G; Edhag O; Dahlqvist R; Andersson I; Magnusson D Lakartidningen; 2008 Sep 17-23; 105(38):2592-3. PubMed ID: 18846865 [No Abstract] [Full Text] [Related]
5. Out-of-pocket costs to users: medicine options for hypertension. Arredondo A Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138 [No Abstract] [Full Text] [Related]
7. HEW promotes wider use of generic drugs, predicts savings under reimbursement plan. Hospitals; 1979 Feb; 53(3):17. PubMed ID: 759296 [No Abstract] [Full Text] [Related]
8. Pharmaceutical Benefits Scheme. Louis WJ; O'Callaghan CJ; Krum H; Mander AG; Louis ES Med J Aust; 1994 Jul; 161(2):174. PubMed ID: 8028551 [No Abstract] [Full Text] [Related]
9. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension]. Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623 [No Abstract] [Full Text] [Related]
10. DTCA not real advertising issue. Saunders B N Z Med J; 2003 Sep; 116(1182):U611. PubMed ID: 14581960 [No Abstract] [Full Text] [Related]
13. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis]. Brun J; Ohlsson-Onerud A; Sörensen N Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431 [No Abstract] [Full Text] [Related]
14. Pharmaceutical Benefits Scheme (PBS). Louis WJ; O'Callaghan CJ; Krum H; Mander AG; Louis ES Med J Aust; 1994 Mar; 160(5):306-7. PubMed ID: 8107635 [No Abstract] [Full Text] [Related]
15. Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals? Granlund D Soc Sci Med; 2009 Dec; 69(11):1643-50. PubMed ID: 19815322 [TBL] [Abstract][Full Text] [Related]
16. DAKOTACARE update: What are we doing about prescription costs? Krafka TL S D Med; 2007 Jun; 60(6):243-4. PubMed ID: 17649865 [No Abstract] [Full Text] [Related]
17. PEI government announces catastrophic drug plan. Birchard K CMAJ; 2013 Jul; 185(10):E432. PubMed ID: 23754110 [No Abstract] [Full Text] [Related]